Evonik Evonik

X
[{"orgOrder":0,"company":"Valensa International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valensa\u2019s Chief Science Officer Presents New Research on Efficacy of a Lipidosterolic Extract of Saw Palmetto","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Valensa International

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Strum’s findings validate the effectiveness of an LSESr like Valensa’s USPlus® Pure Lipidosterolic Extract of Serenoa repens (LSESr), commonly known as saw palmetto, for improved quality of life in men with lower urinary tract symptoms (LUTS).

            Lead Product(s): Serenoa Repens Extract

            Therapeutic Area: Urology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY